Clin2
NCT07184944Worth exploringRecruiting

Study of Duvakitug for moderate to severe Crohn's disease

Crohn's Disease

Treatments studied

Part of Digestive system clinical trials.

This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
751 people
Ages
16 years to 80 years
Study type
Interventional

Who can take part

  • You are between 18 and 80 years old (or 16-17 if you have reached Tanner stage 5 of development, where allowed by local rules)
  • You have moderate to severe Crohn's disease and responded well to treatment in a previous study called STARSCAPE-1, with a follow-up endoscopy
  • You are not allergic to duvakitug or have any other medical condition that would make the study unsafe for you

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07184931Recruiting· Phase 3
Testing duvakitug for active Crohn's disease

This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.

Peoria, Arizona
NCT06548542Recruiting· Phase 2
Targeted therapy study for moderate to severe Crohn's disease

This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.

Dothan, Alabama
NCT07753850Not yet recruiting· Phase 2
Study of a new treatment for Crohn's disease

This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.

NCT06958536Recruiting· Phase 2
Testing a new drug for moderate to severe Crohn's disease

This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.

Tucson, Arizona
NCT06045754Recruiting· Phase 4
Study of vedolizumab with other drugs for Crohn's disease

This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.

Dothan, Alabama
NCT07697456Recruiting· Phase 2
Study of advanced therapies for Crohn's or ulcerative colitis

This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.

Dothan, Alabama

Hear when a new Crohn’s disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.